Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5 Myeloid 2 Lymphoid 2 Thoracic 1 Other solid neoplasm 1 Dermatologic 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 732 Paclitaxel 695 Cyclophosphamide 647 Docetaxel 560 Capecitabine 486 Letrozole 437 Fulvestrant 400 Carboplatin 398 Doxorubicin 341 Tamoxifen 308 Anastrozole 279 pembrolizumab 274 exemestane 258 Epirubicin 251 pertuzumab 240 Radiotherapy 239 palbociclib 224 Bevacizumab 222 Gemcitabine 215 Vinorelbine 197 Lapatinib 181 130-nm albumin-bound paclitaxel 172 Magnetic Resonance Spectroscopy 164 Albumin-Bound Paclitaxel 157 eribulin 154 Surveys and Questionnaires 152 Exercise 151 Drug Therapy 141 Taxes 134 Fluorouracil 133

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

sapacitabine × Breast × Clear all

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡